Update on NMD Pharma’s Phase 2a SYNAPSE-CMT Study

Update on NMD Pharma’s Phase 2a SYNAPSE-CMT Study

We are sharing an update from NMD Pharma regarding topline results from their Phase 2a clinical study called SYNAPSE-CMT. This clinical study explored whether the new, investigational drug ignaseclant (formerly NMD670), could provide benefit adults with...